529 related articles for article (PubMed ID: 26264596)
1. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
4. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
5. [Anti-RANKL antibody for the management of bone metastasis].
Yoneda T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
[TBL] [Abstract][Full Text] [Related]
6. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
[TBL] [Abstract][Full Text] [Related]
7. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for the treatment of bone metastases in advanced breast cancer.
Casas A; Llombart A; Martín M
Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
[TBL] [Abstract][Full Text] [Related]
9. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
Yoneda T
Nihon Rinsho; 2012 Dec; 70(12):2165-71. PubMed ID: 23259391
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
12. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
13. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
Akaza H; Tsukamoto T; Suzuki K; Namiki M; Ozono S; Naitodept S
Gan To Kagaku Ryoho; 2012 Feb; 39(2):207-12. PubMed ID: 22333629
[TBL] [Abstract][Full Text] [Related]
14. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
15. Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.
Perez Ruixo JJ; Doshi S; Sohn W; Chow A
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S85-92. PubMed ID: 25707967
[TBL] [Abstract][Full Text] [Related]
16. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Yee AJ; Raje NS
Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
[TBL] [Abstract][Full Text] [Related]
17. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
18. Targeting RANKL in breast cancer: bone metastasis and beyond.
Azim H; Azim HA
Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
[TBL] [Abstract][Full Text] [Related]
19. [Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].
Takahashi S
Gan To Kagaku Ryoho; 2012 Jan; 39(1):89-94. PubMed ID: 22241358
[TBL] [Abstract][Full Text] [Related]
20. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Udagawa H; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Goto K
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1075-1082. PubMed ID: 28220258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]